GHS Cancer Institute has been awarded $6.7 million to conduct clinical trials and research studies aimed at improving patient outcomes and reducing health disparities. GHS is the only community-based site in S.C. to receive the award.
Clinical trials focus on improving cancer prevention, cancer control, screening for early cancers, and post-treatment surveillance. Cancer care delivery research will focus on quality of life and understanding the diverse and multi-level factors that affect access and quality of care.
Cancer care in the last decade has made many advances. Most of these advances are the result of clinical research through clinical trials or research studies. Clinical trials have resulted in new treatments and prevention options for cancer care.
With a focus on translational research and personalized medicine, GHS’ Institute for Translational Oncology Research (ITOR) provides some of the most advanced cancer treatments available anywhere in the world, while supporting industry’s crucial need to achieve greater efficiency and expediency in bringing life-saving cancer drugs to patients. The effort to advance these dual goals was what led to the creation of ITOR in 2004.
ITOR is a major pillar of translational cancer research at GHS. The efforts of ITOR include a Phase I Clinical Research Unit, a Biorepository Services platform, and proteomics and enomics capabilities.
ITOR advances cancer care on multiple levels, facilitating pioneering research as well as clinical care delivery. ITOR is committed to translational medicine, which is a branch of medical research that forges a direct link between basic research and patient care. In the case of drug therapies, translational medicine refers to the translation of basic research into beneficial drug treatments for patients.
ITOR focuses on discovering and developing drugs that help people who have cancer.
The White House Cancer Moonshot Task Force focuses on making the most of federal investments, targeted incentives, private sector efforts from industry and philanthropy, patient engagement initiatives and other mechanisms to support cancer research and enable progress in treatment and care.
The national initiative, which brings together scientists, oncologists, donors and patients, is intended to galvanize efforts to double the pace of research toward curing cancer. The goal of the moonshot is to double the rate of progress toward a cancer cure – to essentially make a decade’s worth of advances in five years.
Some of the clinical trials discussed during the Moonshot Cancer Summit are already underway at GHS’ Cancer Institute and its Institute for Translational Oncology Research, which works closely with pharmaceutical innovators to develop and test new therapies.
– Jeff Edenfield, MD, medical director of ITOR and the founder of GHS’ Rare Tumor Center.
GHS Human Performance Laboratory (HPL) is the first in the nation to be fully embedded into a cancer research and treatment program.
The HPL, which is working with a limited number of patients on a pilot basis, is a collaborative effort between Greenville Health System and the University of South Carolina School of Medicine Greenville. While its focus is on cancer survivor patients in the GHS Cancer Institute, the lab will ultimately serve all GHS clinical populations.
HPL traditionally have been the province of elite athletes who use the state-of-the-art analysis to improve performance. This the first time that an HPL has been used by a cancer institute to measure the changes in post-treatment cancer survivors — from whole body function all the way down the cellular level — in an effort to improve patient health and outcomes.
Research into understanding and eliminating barriers to accessing high-quality cancer care.